« Back
Home /
Eotaxin Human Recombinant Protein (CCL11)

Eotaxin Human Recombinant Protein (CCL11)

Manufacturer	Boster
Category	Neuroscience Neuroinflammation Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Specific against	other
Format	Lyophilized Powder
Amount	20ug
Item no.	BOS-PROTP51671
Targets	CCL11
eClass 6.1	34160400
eClass 9.0	42020190
Available
Description	Eotaxin Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 74 amino acids and having a molecular mass of 8345.9 Dalton. The CCL11 is purified by proprietary chromatographic techniques.
Gene name	CCL11
Protein function	In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3.
Purification	Greater than 97.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
Shipping	Shipped with wet ice
Short description	Eotaxin Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 74 amino acids and having a molecular mass of 8345.9 Dalton. The CCL11 is purified by proprietary chromatographic techniques.
Storage	Store in -20° C for long term storage. After reconstitution, store in 4° C for short term usage within a few days. Avoid freeze-thaw cycles.
Subcellular localization	Secreted.
Format Information	Sterile Filtered White lyophilized (freeze-dried) powder.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 20ug

available

Delivery expected until 5/30/2024